Improving vaccines for infectious diseases using new adjuvants
Targeting trained immunity and Th1/Th17 axis with combination adjuvants
This study is looking at new ways to make vaccines work better against diseases like tuberculosis and AIDS, so that people can have stronger protection and stay healthier.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11077203 on NIH RePORTER |
What this research studies
This research investigates how new combinations of adjuvants can enhance the effectiveness of vaccines against infectious diseases like tuberculosis and AIDS. By understanding the mechanisms that drive immune responses, the study aims to develop vaccines that can provide better protection. The approach focuses on targeting specific immune cells, such as Th1 and Th17 cells, to improve vaccine-induced immunity. Patients may benefit from more effective vaccines that could lead to better prevention and control of these diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for infectious diseases, particularly those affected by tuberculosis or AIDS.
Not a fit: Patients who are not at risk for infectious diseases or who have already been vaccinated may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines that significantly reduce the incidence of infectious diseases.
How similar studies have performed: Previous research has shown promise in enhancing vaccine efficacy through the use of novel adjuvants, indicating that this approach has potential for success.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Khader, Shabaana a. — University of Chicago
- Study coordinator: Khader, Shabaana a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.